Mechanism of Action of the Group A Streptococcal C5a Inactivator

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1985 Dec 1

PMID 3906656

Citations 78

Authors

D E Wexler

D E Chenoweth

P P Cleary

Affiliations

Soon will be listed here.

Abstract

Virulent group A streptococci have been found to express a cell-surface factor that has the capability of inactivating complement-derived chemotactic factors. To determine the mechanism of action of this factor, we examined the interaction of purified inactivator with pure C5a chemotaxin. Ligand-receptor binding studies demonstrated that streptococcal chemotactic factor inactivator (SCFI)-treated C5a expressed a greatly reduced ability to bind to receptors of polymorphonuclear leukocytes as compared with native C5a. The inactivation of C5a occurred by a nonstoichiometric and temperature-dependent process. NaDodSO4/PAGE analysis indicated that SCFI mediated a small decrease in the molecular weight of C5adesArg, and sequencing of the carboxyl terminus of inactivated C5a demonstrated that a six-residue peptide was lost. The release of discrete peptide fragments from denatured bovine serum albumin upon prolonged incubation with SCFI was indicative of endoprotease activity. Although denatured bovine serum albumin was inefficiently cleaved, native bovine serum albumin and other native proteins were highly resistant to SCFI proteolysis; this indicated that activity was specific in nature.

Citing Articles

Immunostimulatory effects of extracellular membrane vesicles protect oral gingival epithelial cells from periodontal pathobiont damage.

Helliwell E, Rauch I, Nice T, Merritt J, Kreth J Infect Immun. 2025; 93(3):e0053524.

PMID: 39969179 PMC: 11895462. DOI: 10.1128/iai.00535-24.

Characterization of a novel SNP identified in Australian group A isolates derived from the M1 lineage.

Richter J, Cork A, Ong Y, Keller N, Hayes A, Schembri M mBio. 2024; 16(2):e0336624.

PMID: 39688411 PMC: 11796353. DOI: 10.1128/mbio.03366-24.

The complement system: A key player in the host response to infections.

Jayaraman A, Walachowski S, Bosmann M Eur J Immunol. 2024; 54(11):e2350814.

PMID: 39188171 PMC: 11623386. DOI: 10.1002/eji.202350814.

Recent Scientific Advancements towards a Vaccine against Group A .

Fan J, Toth I, Stephenson R Vaccines (Basel). 2024; 12(3).

PMID: 38543906 PMC: 10974072. DOI: 10.3390/vaccines12030272.

Immunomodulating Enzymes from -In Pathogenesis, as Biotechnological Tools, and as Biological Drugs.

Happonen L, Collin M Microorganisms. 2024; 12(1).

PMID: 38258026 PMC: 10818452. DOI: 10.3390/microorganisms12010200.

References

Goetzl E, Austen K . Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest. 1974; 53(2):591-9. PMC: 301503. DOI: 10.1172/JCI107594. View

Hugli T, MULLER-EBERHARD H . Anaphylatoxins: C3a and C5a. Adv Immunol. 1978; 26:1-53. DOI: 10.1016/s0065-2776(08)60228-x. View

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Bokisch V, MULLER-EBERHARD H . Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970; 49(12):2427-36. PMC: 322744. DOI: 10.1172/JCI106462. View

Ferrante A, Thong Y . A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J Immunol Methods. 1978; 24(3-4):389-93. DOI: 10.1016/0022-1759(78)90143-6. View

Chenoweth D, Hugli T . Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol. 1980; 17(2):151-61. DOI: 10.1016/0161-5890(80)90067-x. View

Oakley B, Kirsch D, Morris N . A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels. Anal Biochem. 1980; 105(2):361-3. DOI: 10.1016/0003-2697(80)90470-4. View

Chenoweth D, Goodman M, Weigle W . Demonstration of a specific receptor for human C5a anaphylatoxin on murine macrophages. J Exp Med. 1982; 156(1):68-78. PMC: 2186737. DOI: 10.1084/jem.156.1.68. View

Snyderman R, Phillips J, Mergenhagen S . Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates. J Exp Med. 1971; 134(5):1131-43. PMC: 2139022. DOI: 10.1084/jem.134.5.1131. View

10.

Wexler D, Nelson R, Cleary P . Human neutrophil chemotactic response to group A streptococci: bacteria-mediated interference with complement-derived chemotactic factors. Infect Immun. 1983; 39(1):239-46. PMC: 347932. DOI: 10.1128/iai.39.1.239-246.1983. View

11.

Huey R, Bloor C, Kawahara M, Hugli T . Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol. 1983; 112(1):48-60. PMC: 1916315. View

12.

Goldstein I, Brai M, OSLER A, Weissmann G . Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation. J Immunol. 1973; 111(1):33-7. View

13.

Becker E, Showell H, Henson P, Hsu L . The ability of chemotactic factors to induce lysosomal enzyme release. I. The characteristics of the release, the importance of surfaces and the relation of enzyme release to chemotactic responsiveness. J Immunol. 1974; 112(6):2047-54. View

14.

Schultz D, Miller K . Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors. Infect Immun. 1974; 10(1):128-35. PMC: 414968. DOI: 10.1128/iai.10.1.128-135.1974. View

15.

Goldstein I, Feit F, Weissmann G . Enhancement of nitroblue tetrazolium dye reduction by leukocytes exposed to a component of complement in the absence of phagocytosis. J Immunol. 1975; 114(1 Pt 2):516-8. View

16.

Goldstein I, Roos D, Kaplan H, Weissmann G . Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest. 1975; 56(5):1155-63. PMC: 301978. DOI: 10.1172/JCI108191. View

17.

Fernandez H, Hugli T . Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol. 1976; 117(5 Pt 1):1688-94. View

18.

Schlievert P, Bettin K, Watson D . Purification and characterization of group A streptococcal pyrogenic exotoxin type C. Infect Immun. 1977; 16(2):673-9. PMC: 421008. DOI: 10.1128/iai.16.2.673-679.1977. View

19.

Fernandez H, Henson P, Otani A, Hugli T . Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978; 120(1):109-15. View

20.

Fernandez H, Hugli T . Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem. 1978; 253(19):6955-64. View